Pharmaceutical company Merck has attempted to expand the use of Gardasil to older women, but the FDA has put up a roadblock.
Submitted by Joan R. Neubauer on 2011-10-12
Gardasil, the vaccine used to prevent HPV in young women under 25 years of age is once again in the spotlight. While manufacturer Merck has attempted to expand its use to older women, the Food and Drug Administration (FDA) has stopped Merck’s efforts to extend use of the vaccine in women up to age 45. The FDA has concerns about possible side effects of the drug which has been tied to over “49 deaths along with countless negative reactions that have led to hospitalizations and crippled health,” as reported by Anthony Gucciardi for activistpost.com.
The FDA claims that Merck’s clinical data failed to demonstrate the effectiveness of Gardasil in women 27 to 45 years old. As a result, Merck must also change the label on the vaccine that states, the product “has not been demonstrated to prevent HPV-related cervical intraepithelial neoplasia 2/3 or worse in women older than 26 years of age.”
Since its release, Gardasil has met with controversy over its effectiveness and safety for women of any age. Recently, tests produced the disturbing finding of rDNA inside the vaccine vials collected from the United States, Australia, New Zealand, Spain, Poland, and France. SANE Vax, a vaccine research organization, tested vials of Gardasil to learn why the vaccine has resulted in so many deaths and adverse health reactions. They found more than a dozen of the Gardasil vaccine vials were contaminated with the rDNA of the human Papillomavirus Virus (HPV).
This rDNA does not occur naturally and has serious implications. It is the result of genetically modified HPV virus, a heavily altered form of HPV, added to the vaccine during the manufacturing process.